Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacl.2020.08.011 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum pcsk9
4
pcsk9 inhibition
4
inhibition alirocumab
4
alirocumab pediatric
4
pediatric patients
4
patients heterozygous
4
heterozygous familial
4
familial hypercholesterolemia
4
hypercholesterolemia odyssey
4
odyssey kids
4
Similar Publications
Corrigendum to "Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia" [Nanomedicine 40 (2022 Feb); 102480. doi: 10.1016/j.nano.2021.102480].
Nanomedicine
November 2022
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA. Electronic address:
Corrigendum: Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State.
Front Cardiovasc Med
January 2022
Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland.
[This corrects the article DOI: 10.3389/fcvm.2021.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!